Daniel Lynch

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Raised $244,300,000.00 from Bain Capital Life Sciences and Rock Springs Capital.

SpringWorks Therapeutics is a biopharmaceutical company that develops medicines for patients with severe rare diseases and cancer.

Raised $1,015,500,000.00 from EcoR1 Capital, Boxer Capital, Invus Opportunities, Deerfield and Perceptive Advisors.

Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.

Raised $2,367,800,000.00 from Royalty Pharma, Sixth Street and Cowen Investment Management.

Bluebird Bio is a biopharma company that develops and commercializes gene therapies for the treatment of severe genetic diseases and cancer.

Raised $3,436,600,000.00 from Hercules Capital.

Surface Oncology develops next-generation cancer immunotherapy treatments based on proprietary discoveries.

Raised $88,900,000.00 from RS Investments, Venrock Healthcare Capital Partners, Biotechnology Value Fund and EcoR1 Capital.

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, a class of highly selective, targeted therapeutics.

Raised $91,847,684.00 from RUSNANO.

Ember Therapeutics develops the power of brown fat biology and insulin sensitization to develop treatments for metabolic diseases.

Raised $34,000,000.00 from Third Rock Ventures.